Exam 1 Quiz 2: Pharmacodynamics Pt 2 Flashcards

1
Q

study of the physiological and biochemical interaction of drug molecules with cell receptors in target tissue that respond to hormones

A

pharmacodynamics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

receptors

A

proteins on cell surface or within cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ligand

A

chemical or molecule that binds to a receptor with some selectivity
can be a neurotransmitter or a drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

distinct site on the surface of the receptor different from where neurotransmitter binds
- impacts function of the receptor

A

allosteric binding site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

strength of the bond between the drug and the receptor

- how much does the drug like the receptor

A

binding affinity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

drugs ability to alter the activity of the receptor

- what is the drug doing? is there a biological response to the drug?

A

receptor efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what is receptor efficacy typically compared to

A

endogenous ligand

  • naturally occurring chemical in your body
    ex: comparing cocaine to dopamine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

has the best chemical fit (highest affinity)
attaches readily to the receptor and produces a significant biological effect
mimic the endogenous ligand

A

receptor agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

do receptor agonists always have an excitatory response? explain

A

no

it depends on the receptor, if the receptor is inhibitory you will get an IPSP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

fit receptors but produce no cellular effect (low efficacy)

can prevent active ligands from binding

A

receptor antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

have intermediate efficacy - not a huge effect but still binds

A

partial agonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

initiate biological action that is opposite to that produced by an agonist

A

inverse agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

2 forms of antagonists

A

competitive and noncompetitive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

bind the same site as a neurotransmitter to prevent the neurotransmitter from binding to and activating receptors

A

competitive antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

do NOT prevent neurotransmitter binding
Prevent activation of receptor by binding to other sites
- interacts with endogenous ligand

A

noncompetitive antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

2 types of allosteric regulators and what they are

A

positive modulators: bind to allosteric sites on receptor and INCREASE the ability of neurotransmitter to bind to and or activate the receptor (amplifies it)

negative modulators: bind to allosteric sites and DECREASE ability of neurotransmitter to bind and or activate receptor (diminishes it - like a whisper)

17
Q

upregulation vs down regulation

A

up regulation: inc # of receptors - inc chance of a biological response

down regulation: dec # receptors in response to absence of ligands or chronic activation - dec chance of biological response

18
Q

dose response curve purpose

A

how much (dose/amount) of a drug (x-axis) causes a particular effect on the body (y-axis)

19
Q

smallest dose that produces a measurable effect

A

threshold dose

20
Q

amount of drug needed to occupy all receptors (the peak)

A

maximum response

21
Q

drug dose that produces on average, a specified all or none response in 50% of the test population
- at what dose do you need to get a response from 50%

A

ED50 (effective dose 50%)

22
Q

ED100

A

dose that produces maximal effect in 100% of he population

how high of a dose do you need to give to reach 100%

23
Q

toxic dose

A

TD50

dose at which 50% of the population gets adverse reactions (side effects)

24
Q

lethal dose

A

LD50
dose at which 50% of the population die
- not seen for humans usually animals

25
Q

therapeutic index

A

TI
TD50/ED50
what range of values can we prescribe with benefits that out weigh the side effects

26
Q

amount of drug needed to produce a given effect
determined by affinity of drug for receptor and # of receptors available
determined by ED50 value

A

potency

27
Q

more potent drugs require____

A

lower doses to produce the effect

most potent is more to the left on a graph

28
Q

maximum effect/response a drug can produce what response we are getting
more drug - has no effect - but may inc side effects
highest values on graph = highest

A

efficacy

29
Q

what is the purpose of the therapeutic index

A

calculates drug safety

- provides dose range and accounts for side effects

30
Q

these can be replaced by an excess of agonist

  • replace the endogenous ligand molecule
  • shift potency to the right
A

competitive antagonists

31
Q

competitive antagonist example

A

naloxone is competitive antagonist of morphine

  • makes it harder to produce the biological response - increases the amount fo drug needed to cause effects
32
Q

how do noncompetitive antagonists reduce the effects of agonists (3)

A
  1. bind to allosteric sites
  2. disturb cell membrane supporting the receptor
  3. interfere with cell processes initiated by agonist

change magnitude of biological response
- can effect both potency and efficacy or jus tone or the other

33
Q

example of a noncompetitive antagonist

A

want pain relief without the sedative effects
- with these you get as close as possible to pain relief without getting the toxic side effects

  • usually given to prevent an overdose
34
Q

2 drugs interact and reduce effectiveness of both drugs

A

physiological antagonism

35
Q

both drugs taken together cause a combined greater effect

A

additive effects

36
Q

combination of 2 drugs produces effects greater than the sum of their individual effects

A

potentiation (drug synergy)

37
Q

what can a longer half life lead to

A

accumulatio which increases potential for side effects and toxicity

38
Q

target therapeutic concentration is achieved only after ____

A

multiple doses

39
Q

half life determines the time needed to reach the study state plasma level which is when _____

A

absorption/distribution phase is equal to the metabolic/excretion phase